Naurex is a biopharmaceutical company specializing in developing novel modulators of the NMDA receptor to treat challenging diseases of the central nervous system (CNS), with a particular focus on major depressive disorder (MDD) and other CNS conditions[1][5]. Its products aim to optimize synaptic function, addressing unmet medical needs in mental health. Naurex serves patients with difficult-to-treat CNS diseases, offering innovative therapeutic options where traditional treatments often fail. The company has demonstrated strong growth momentum, culminating in its acquisition by Allergan (now part of AbbVie), which has enabled its promising antidepressant programs to advance into late-stage clinical trials and toward market entry[2][3].
Founded in late 2006 as a spin-off from Northwestern University, Naurex emerged from the research of Joe Moskal, who was driven by a desire to understand cognition rather than purely commercial goals[2]. The company grew steadily, supported by Northwestern’s innovative environment and collaborations with world-class researchers and students. Early traction came with a significant $18 million financing round in 2011, attracting experienced pharmaceutical veterans like Bill Gantz and Riedel, who brought industry expertise and connections to the company[2][4]. Over nearly a decade, Naurex evolved from a small startup into a valuable biopharma firm, culminating in its acquisition by Allergan in a deal valued at $560 million upfront plus milestone payments[2].
Naurex rides the growing trend of precision neuroscience and innovative CNS therapeutics, addressing the significant unmet need in mental health treatment where many patients do not respond to existing drugs. The timing is favorable due to increasing recognition of CNS disorders’ societal impact and advances in molecular neuroscience enabling targeted therapies. Market forces such as rising mental health awareness, regulatory support for novel CNS drugs, and pharmaceutical industry interest in breakthrough therapies work in Naurex’s favor. Its success exemplifies the value of academic spin-offs in translating cutting-edge research into commercial biopharma innovations, influencing the broader ecosystem by encouraging similar university-industry collaborations[2][4].
Looking ahead, Naurex’s integration with AbbVie positions it well to bring its novel CNS therapies to market, potentially transforming treatment paradigms for depression and other CNS disorders. Trends shaping its journey include advances in neuropharmacology, personalized medicine, and growing investment in mental health innovation. As the company’s programs progress through clinical development, its influence may expand by validating NMDA receptor modulation as a therapeutic strategy, inspiring further research and development in this space. Naurex’s trajectory from academic spin-off to a key player in CNS drug development underscores the importance of sustained scientific innovation combined with strategic industry partnerships.
Naurex has raised $98.0M in total across 2 funding rounds.
Naurex's investors include ALSA Ventures, Soffinova Partners.
Naurex has raised $98.0M across 2 funding rounds. Most recently, it raised $80.0M Series C in December 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2014 | $80.0M Series C | ALSA Ventures, Soffinova Partners | |
| May 1, 2011 | $18.0M Series A | ALSA Ventures, Soffinova Partners |
